Stephen B. Willingham

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index9.3kcitations69works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Adenosine and Purinergic Signaling(21), Inflammasome and immune disorders(15), Phagocytosis and Immune Regulation(15), Cancer Immunotherapy and Biomarkers(14), Immunotherapy and Immune Responses(8)

Publications68 total

Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
2023Open Access
Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
2023Open Access
Data from A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
2023Open Access
Supplementary Data from A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
2023Open Access
Data from A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
2023Open Access
Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
2023Open Access
Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
2023Open Access
Supplementary Data from A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
2023Open Access
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
Journal for ImmunoTherapy of Cancer·2022· 22 citedOpen Access
Circulating tumor DNA (ctDNA) detection of molecular residual disease (MRD) as a potential biomarker in localized soft tissue sarcoma (STS).
Journal of Clinical Oncology·2022· 1 cited
Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
2021· 3 citedOpen Access
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
Proceedings of the National Academy of Sciences·2021· 115 citedOpen Access
Abstract PS17-06: Humanized anti-CD47 monoclonal antibody magrolimab (Hu5F9-G4) plus trastuzumab potentiates antibody-dependent cellular phagocytosis (ADCP), and cooperate to inhibit human HER2+ breast cancer (BC) xenografts growth <i>in vivo</i>
Cancer Research·2021· 1 cited
Cutting Edge: NLRC5-Dependent Activation of the Inflammasome
UNC Libraries·2020Open Access
Cutting Edge: Inflammasome Activation by Alum and Alum's Adjuvant Effect Are Mediated by NLRP3
UNC Libraries·2020· 33 citedOpen Access
Neisseria gonorrhoeae Activates the Proteinase Cathepsin B to Mediate the Signaling Activities of the NLRP3 and ASC-Containing Inflammasome
UNC Libraries·2020· 22 citedOpen Access
NLRP3 (NALP3, Cryopyrin) Facilitates In Vivo Caspase-1 Activation, Necrosis, and HMGB1 Release via Inflammasome-Dependent and -Independent Pathways
UNC Libraries·2020Open Access
Microbial Pathogen-Induced Necrotic Cell Death Mediated by the Inflammasome Components CIAS1/Cryopyrin/NLRP3 and ASC
UNC Libraries·2020Open Access
325 Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells
Regular and Young Investigator Award Abstracts·2020· 1 citedOpen Access
Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
2020· 9 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Irving L. Weissman(18), Richard A. Miller(14), Andrew Hotson(12), Po Y. Ho(10), Ian McCaffery(9), Kipp Weiskopf(8), Jenny P.‐Y. Ting(7), Humberto Contreras-Trujillo(6), Jens-Peter Volkmer(6), Joseph A. Duncan(6), Dan T. Bergstralh(6), Ginna G. Laport(6), Ravindra Majeti(5), Matt van de Rijn(5), Anne Kathrin Volkmer(4), Badreddin Edris(4), Max T. Huang(4), Debra J. Taxman(4), Lawrence Fong(4), Brett Hughes(4)